Home
About me
Contact us
health care
Home-icon
Male
Women
stressless
Relationship
Obstetrics
Motivation
Yoga
Home
health-issue
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
Nitesh sinha
May 30, 2023
https://ift.tt/5dIMsiG
from Sanofi - Aventis Groupe https://ift.tt/QKG45mV
via
IFTTT
Post a Comment
0 Comments
Powered by Blogger
September 2024
6
August 2024
2
July 2024
5
June 2024
8
May 2024
11
April 2024
5
March 2024
2
February 2024
11
January 2024
4
December 2023
6
November 2023
3
October 2023
10
September 2023
7
August 2023
21
July 2023
23
June 2023
24
May 2023
47
April 2023
37
March 2023
29
February 2023
40
January 2023
27
December 2022
21
November 2022
22
October 2022
162
September 2022
206
August 2022
188
July 2022
200
June 2022
187
May 2022
172
April 2022
180
March 2022
135
February 2022
115
January 2022
85
December 2021
49
November 2021
44
October 2021
34
September 2021
17
August 2021
10
July 2021
9
For any kind of information / suggestion / Advice. MAIL IT.
Name
Email
*
Message
*
Followers
Followers
Ads
Ad Space
Responsive Advertisement
Popular Posts
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
September 11, 2024
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
May 31, 2024
Labels
0 Comments
Please ,
Do not enter any kind of span link